Literature DB >> 25755610

Role of surveillance in prevention of hepatocellular carcinoma.

Dipanjan Panda1.   

Abstract

Hepatocellular carcinoma is a common malignancy and one of the important public health problems in India. The surveillance of hepatocellular carcinoma (HCC) is an established approach to detect early cancers in patients with defined risks. However, there are still controversies and issues to be addressed regarding the optimal surveillance methods and interval. The current level of awareness among physicians in India about surveillance is low and the need and most cost effective surveillance strategy in developing country like ours is unclear. This article has tried to discuss these issues in their appropriate perspective. To address this complicated issue, a multicenter randomized prospective study however may be required.

Entities:  

Keywords:  AFP, alpha-fetoprotein; CI, confidence interval; CLD, chronic liver disease; DCP, des-γ-carboxy-prothrombin; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NAFLD, Nonalcoholic Fatty Liver Disease; NASH, nonalcoholic steatohepatitis; QI, quality improvement; RCT, randomized controlled trial; TPCT, triple phase CT scan; US, ultrasound; USG, ultra sonogram; USG, ultrasonography; cost effective strategy; hepatocellular carcinoma; prevention; surveillance

Year:  2014        PMID: 25755610      PMCID: PMC4284238          DOI: 10.1016/j.jceh.2014.03.044

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  46 in total

1.  Surveillance for hepatocellular carcinoma in patients with liver cirrhosis in India.

Authors:  Rakesh Aggarwal
Journal:  Trop Gastroenterol       Date:  2008 Oct-Dec

2.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Verslype; O Rosmorduc; P Rougier
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?

Authors:  Hossein Poustchi; Geoffrey C Farrell; Simone I Strasser; Alice U Lee; Geoffrey W McCaughan; Jacob George
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

4.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

Authors:  Franco Trevisani; Stefania De Notariis; Gianludovico Rapaccini; Fabio Farinati; Luisa Benvegnù; Marco Zoli; Gian Luca Grazi; Poggio Paolo Del; NolfoMariaAnna Di; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

5.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

6.  Subclinical hepatocellular carcinoma: an analysis of 391 patients.

Authors:  Z Y Tang; Y Q Yu; X D Zhou; B H Yang; Z C Ma; Z Y Lin
Journal:  J Surg Oncol Suppl       Date:  1993

7.  Pattern and management of recurrent hepatocellular carcinoma after liver transplantation.

Authors:  E Regalia; L R Fassati; U Valente; A Pulvirenti; I Damilano; G Dardano; F Montalto; J Coppa; V Mazzaferro
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

8.  Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India.

Authors:  Shashi Bala Paul; Vishnubhatla Sreenivas; Manpreet Singh Gulati; Kaushal Madan; Arun Kumar Gupta; Sima Mukhopadhyay; Subrat Kumar Panda; Subrat Kumar Acharya
Journal:  Indian J Gastroenterol       Date:  2007 Nov-Dec

9.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  2 in total

1.  Hepatobiliary quiz-12 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12

Review 2.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.